57 results about "Disulfide group" patented technology

Disclosed is a method of making conjugates of cell binding agents and small molecule drugs comprising reacting a cell binding agent with a bifunctional cross-linking moiety to thereby provide the cell binding agent with a reactive disulfide group and then reacting the modified cell binding agent with a small molecule drug comprising a free thiol group. Bifunctional cross-linking moieties are also disclosed.

An electrode includes an electrically conductive matrix containing a disulfide group, wherein an S-S bond of the disulfide group is cleaved by electrochemical reduction and reformed by electrochemical oxidation. A plurality of carbon nanotubes is dispersed in the electrically conductive matrix. The electrode can be used as a cathode of a lithium battery.

A composition useful for nitrate removal, and treatment of water, selected from mining, agriculture industries, military operations, or others water stream, or industrial waters, livestock wastewater and a livestock water stream or from other sources, which comprises a sufficient amount of organic modified clay, a highly crosslinked carbohydrate polymer with branched-chain structure and having present sulfide or disulfide group, or alloy or blend with triazine-trithione sodium salt, high swelling sodium bentonite or calcium bentonite, and activated carbon, without pH adjustment, and/or presents of electropositive metals inorganic acid or alkaline compounds.

It is an object of the present invention to provide a polyion complex used as a non-viral gene vector, which achieves sufficiently high gene expression efficiency to a target cell. The polyion complex of the present invention comprises a block copolymer formed by binding polyethylene glycol to polycation via a disulfide group and a nucleic acid.

Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.

The invention relates to corrosion-inhibiting sol-gel coating systems and methods. Corrosion-inhibiting coating materials comprise a sol-gel and a corrosion-inhibiting compound with at least one disulfide group. The corrosion-inhibiting compound is contained within the sol-gel. Coated and/or laminated structures may include the corrosion-inhibiting coating materials on a metal substrate, and may include a secondary layer (e.g., a paint, etc.) adhered to the coating material opposite the metal substrate. Methods of forming a corrosion-inhibiting sol-gel comprise mixing organo-metallic compounds and the corrosion-inhibiting compound into a sol solution and incubating (e.g., reacting) the sol solution to form the corrosion-inhibiting sol-gel with the corrosion-inhibiting compound contained within the sol-gel. Generally, corrosion-inhibiting coating materials are hexavalent chromium free.

The invention relates to a graphene oxide drug carrier and an anti-tumor drug as well as a preparation method of the anti-tumor drug. The graphene oxide drug carrier comprises multiple nano-particles, wherein each nano-particle comprises an inner core formed by graphene oxide and a shell formed by pyrenyl disulfide group polyethylene glycol, and the pyrenyl disulfide group polyethylene glycol is adhered to the surface of the graphene oxide through the pi-pi conjugative effect of pyrenyl and the graphene oxide. The modification effect of the pyrenyl disulfide group polyethylene glycol ensures that the graphene oxide drug carrier has the characteristics of relatively high space stability, electrostatic stability and has relatively high stability.

The present invention provides a chemical sensor for dopamine detection. The chemical sensor comprises gold-containing nanoparticles, wherein the surface of the gold-containing nanoparticles is modified by class A organic function small molecules and class B organic function small molecules, the class A organic function small molecules contain a boric acid group capable of acting with o-diphenol hydroxyl in the dopamine molecule, the class B organic function small molecules contain one or a plurality of materials selected from a crown ether group, an aldehyde group, succimide activated carboxyl, a phosphate ion group and a sulfonate ion group and capable of acting with the protonated terminal amino group in the dopamine molecule, and the class A organic function small molecules and the class B organic function small molecules further contain one or a plurality of materials selected from pyridine, mercapto, a primary amine group and a disulfide group so as to modify the gold-containing nanoparticles. The invention further provides a preparation method for the chemical sensor, a method for detecting dopamine, and an application of the chemical sensor in dopamine detection apparatuses.

The present invention discloses a linked disulfide group substituted deuteroporphyrin, metal complexes, preparation method and uses thereof, wherein linked disulfide group substituted deuteroporphyrin and metal complexes thereof, first using thionyl chloride and cystineto prepare cystine methyl ester hydrochloride solid; then using deuteroporphyrin, cystine methyl ester hydrochloride, dicyclohexylcarbodiimide DCC and N, N-dimethylformamide DMF to prepare linked disulfide group substituted deuteroporphyrin in the presence of catalyst pyridine. Then dissolving the linked disulfide group substituted deuteroporphyrin solid in chloroform, adding metal salts and proceeding refluxing reaction to get the linked disulfide group substituted deuteroporphyrin metal complexes. The invention provided linked disulfide group substituted deuteroporphyrin and metal complexes thereof are novel compounds capable of improving catalyst activity and selectivity, shorting reaction time, improving cyclohexane transformation ratio and selectivity of the cyclohexanone (cyclohexanol) in products.

Provided is a thin film transistor array which does not employ photolithography for the formation of an interlayer insulating film and has few defects in the interlayer insulating film. This thin film transistor array is provided at least with an insulating substrate (10), a gate electrode (11), a gate insulating film (12), a source electrode (13B), a drain electrode (14), a semiconductor layer (15), a protection layer (16) that covers the semiconductor layer (15), a pixel electrode (18), and an interlayer insulating film (17) that is formed between the drain electrode (14) and the pixel electrode (18). The interlayer insulating film (17) is an organic film or an organic-inorganic mixed film, and in order to connect the pixel electrode (18) to the drain electrode (14), the interlayer insulating film (17) has a via hole (40) in a part of the portion where the drain electrode (14) is formed. The drain electrode (14) has an opening portion that is positioned within the via hole (40) and is obtained by forming an opening in the electrode material, and a thiol group or a disulfide group is present on the drain electrode (14) within the via hole (40).

Provided are an etching fluid that is capable of suppressing side etching while not impairing the linearity of copper wiring, a replenishing fluid for the same, and a method for forming copper wiring. This etching fluid is a copper etching fluid characterized in being an aqueous solution containing acid, oxidizing metal ions, and a compound (A), the compound (A) having in molecules thereof an amino group and at least one sulfur-containing functional group selected from the group consisting of thiole groups, sulfide groups, and disulfide groups (where the sulfide and disulfide groups are groups in which the sulfur atoms and the heteroatoms linked thereto are linked by a single bond, and which do not form π conjugates).

The invention discloses a nanoemulsion of N-[4-(2,4 dimethoxy phenyl)-5-oxygroup-4,5-dihydro-[1,2] disulfide group-[4,3-b]-6-pyrryl]-3,5-di-trifluoromethyl benzamide and a preparation method thereof. The nanoemulsion is prepared from medicines, a water phase, an oil phase, an emulsifier, an assistant emulsifier, and the like and can enhance the dispersity of the medicines and promote the absorption of the medicines so as to further enhance the bioavailability of the medicines. The nanoemulsion has low toxicity, no hemolysis, and the like, is beneficial to the absorption of the medicines and has the advantages of simple and easy preparation method, safe and non-toxic operation, low preparation cost, high medicine content and no medicine loss. The invention is used for preparing the nanoemulsion of the N-[4-(2,4 dimethoxy phenyl)-5-oxygroup-4,5-dihydro-[1,2] disulfide group-[4,3-b]-6-pyrryl]-3,5-di-trifluoromethyl benzamide.

The invention discloses a silk fabric which comprises the following raw materials by mass: 4-9 parts of fibrous protein fibroin, 1-3 parts of solid fatty acid, 1-2 parts of cellulosic fibers, 2-4 parts of dimetyl terephthalate, 2-5 parts of polyamide fibers, 1-5 parts of disulfide groups, and 3-8 parts of acetate fibers. The silk fabric of the invention is smooth, soft, and rich in gloss, provides feeling of being warm in winter and cool in summer, has very good extensibility, and good heat resistance, is easy to clean, is not easy to generate static electricity, is not easy to absorb dust or moisture, and is applicable to users with various skin qualities.

The graft copolymer comprises a polymerizable monomer (A1) represented by general formula (III) and a polymerizable monomer (B1) containing a pyridyl group, and a ligand can be bonded via the functional group at the terminus of R^3a. In the formula, R^1a represents a polymerizable group, R^2a represents an alkylene group having a carbon number of 2-5, R^3a represents an organic group having at a terminus a functional group selected from among an azide group, a phenyl azide group, a carboxyl group, a primary to quaternary amino group, an acetal group, an aldehyde group, a thiol group, a disulfide group, an active ester group, a trialkoxysilyl group, and a polymerizable group, and n represents any integer from 5 to 20,000.

The invention discloses a targeted anti-bladder-cancer albumin carrying mitomycin drug and a preparation method thereof. The targeted anti-bladder-cancer albumin carrying mitomycin drug is characterized in that drug molecules contain albumin molecules, anti-human-bladder-cancer monoclonal antibodies (BDI-1) and mitomycin (MMC), and the synthetic method of the drug molecules comprises the following steps: using glutaraldehyde as a cross-linking curing agent, and combining mitomycin molecules with bovine blood albumin molecules to be prepared into albumin carrying mitomycin (MMC-NS) nanoparticles with the particle size being 280-350 nanometer; then using a heterogenic bifunctional coupling agent N-succinimido-3-(2-pyridyl disulfide) propionate (SPDP) to causes the albumin carrying mitomycin molecules to be coupled with a pyridyl disulfide group (PDP) to obtain MMC-NS-PDP molecules; and finally, causing MMC-NS-PDP to reacting with BDI-1-SH molecules to obtain the drug with the molecules containing anti-human-bladder-cancer antibodies, the albumin molecules and the mitomycin, namely the targeted anti-bladder-cancer albumin carrying mitomycin drug, (BDI-1-MMC-NS for short). The drug has strong targeting to bladder cancer, a strong curative effect on bladder cancer, and a smaller influence on normal tissue cells.